Europe Influenza Vaccines Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Vaccine Type (Quadrivalent Vaccines and Trivalent Vaccines), Virus Type (Influenza Virus Type A and Influenza Virus Type B), Technology (Egg-based and Cell-base
Description
Europe Influenza Vaccines Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Vaccine Type (Quadrivalent Vaccines and Trivalent Vaccines), Virus Type (Influenza Virus Type A and Influenza Virus Type B), Technology (Egg-based and Cell-based), and Route of Administration (Injection and Nasal Spray)
The influenza vaccines market in Europe is expected to grow from US$ 2,261.85 million in 2022 to US$ 3,424.02 million by 2028. It is estimated to grow at a CAGR of 7.2% from 2022 to 2028.
Increasing Investment by Top Market Players and Governments
Market players and governments are increasing their investments in vaccine development and immunization. In June 2021, The European Investment Bank signed a US$ 30.55 million global vaccine distribution agreement with biotech company Univercells to mass produce the COVID-19 vaccine at a new Belgian site. It helped build other vaccine factories around the region. In April 2022, the Bank provided a US$ 15.27 million loan to Italian biomedical research company IRBM to expand its vaccine production capacity and strengthen research on coronaviruses and other diseases. Thus, the increase in investment by top market players and governments is bolstering the influenza vaccines market.
Market Overview
Europe is the second largest market in the forecast period owing to factors such as rising geriatric population, increasing prevalence of flu and related illness, and high demand for the development of new vaccines in the region. In addition, growing funding for research & development activities is likely to add more opportunities in coming years, in the region. The pharmaceutical industry is continuously expanding in the UK. Under the UK’s pharmaceutical industry, over 610 companies are operating. According to Office National Statistics, 610 companies were operating in the UK in 2018. It has over 15 global companies headquartered in the UK. Also, nearly 41% of pharmaceutical production is exported to other countries and regions. Companies such as Astra Zeneca, Eli Lilly, and GSK have contributed significantly to the growth of pharmaceuticals and led research and development at a peak. The growth of these companies and expansions in the business segments is expected to influence market growth in the following years. The seasonal influenza vaccination programme was introduced in England during the late 1960s to protect those in clinical risk groups. During 2020 to 2021 an expanded offer was made which enabled people aged 50 to 64 years to receive the flu vaccine as part of an NHS funded programme. This offer will continue for this age group, as a temporary measure, for the 2021 to 2022 programme. Thus, the factors mentioned above are driving the market growth of influenza vaccines.
Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Million)
Europe Influenza Vaccines Market Segmentation
The Europe Influenza Vaccines Market is segmented into vaccine type, virus type, technology, route of administration, and country.
Based on vaccine type, the Europe influenza vaccines market is divided into quadrivalent vaccines and trivalent vaccines. The quadrivalent vaccines segment registered the larger market share in 2022.
Based on virus type, the Europe influenza vaccines market is segmented into influenza virus type A and influenza virus type B. The influenza virus type A segment held a larger market share in 2022.
Based on technology, the Europe influenza vaccines market is divided into egg-based and cell-based. The egg-based segment held a larger market share in 2022.
Based on route of administration, the Europe influenza vaccines market is divided into injection and nasal spray. The injection segment held a larger market share in 2022.
Based on country, the market is segmented into the UK, Germany, France, Italy, Spain, and the rest of Europe. The UK dominated the market share in 2022.
AstraZeneca; Emergent BioSolutions Inc.; GlaxoSmithKline plc.; Hualan Biological Engineering Inc.; Mitsubishi Chemical Group Corporation; Moderna, Inc.; MYLAN N.V.; Sanofi; SEQIRUS; and Serum Institute of India Pvt. Ltd are the leading companies operating in the influenza vaccines market in Europe.
Reasons to buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe Influenza Vaccines Market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Europe Influenza Vaccines Market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Influenza Vaccines Market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution
The influenza vaccines market in Europe is expected to grow from US$ 2,261.85 million in 2022 to US$ 3,424.02 million by 2028. It is estimated to grow at a CAGR of 7.2% from 2022 to 2028.
Increasing Investment by Top Market Players and Governments
Market players and governments are increasing their investments in vaccine development and immunization. In June 2021, The European Investment Bank signed a US$ 30.55 million global vaccine distribution agreement with biotech company Univercells to mass produce the COVID-19 vaccine at a new Belgian site. It helped build other vaccine factories around the region. In April 2022, the Bank provided a US$ 15.27 million loan to Italian biomedical research company IRBM to expand its vaccine production capacity and strengthen research on coronaviruses and other diseases. Thus, the increase in investment by top market players and governments is bolstering the influenza vaccines market.
Market Overview
Europe is the second largest market in the forecast period owing to factors such as rising geriatric population, increasing prevalence of flu and related illness, and high demand for the development of new vaccines in the region. In addition, growing funding for research & development activities is likely to add more opportunities in coming years, in the region. The pharmaceutical industry is continuously expanding in the UK. Under the UK’s pharmaceutical industry, over 610 companies are operating. According to Office National Statistics, 610 companies were operating in the UK in 2018. It has over 15 global companies headquartered in the UK. Also, nearly 41% of pharmaceutical production is exported to other countries and regions. Companies such as Astra Zeneca, Eli Lilly, and GSK have contributed significantly to the growth of pharmaceuticals and led research and development at a peak. The growth of these companies and expansions in the business segments is expected to influence market growth in the following years. The seasonal influenza vaccination programme was introduced in England during the late 1960s to protect those in clinical risk groups. During 2020 to 2021 an expanded offer was made which enabled people aged 50 to 64 years to receive the flu vaccine as part of an NHS funded programme. This offer will continue for this age group, as a temporary measure, for the 2021 to 2022 programme. Thus, the factors mentioned above are driving the market growth of influenza vaccines.
Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Million)
Europe Influenza Vaccines Market Segmentation
The Europe Influenza Vaccines Market is segmented into vaccine type, virus type, technology, route of administration, and country.
Based on vaccine type, the Europe influenza vaccines market is divided into quadrivalent vaccines and trivalent vaccines. The quadrivalent vaccines segment registered the larger market share in 2022.
Based on virus type, the Europe influenza vaccines market is segmented into influenza virus type A and influenza virus type B. The influenza virus type A segment held a larger market share in 2022.
Based on technology, the Europe influenza vaccines market is divided into egg-based and cell-based. The egg-based segment held a larger market share in 2022.
Based on route of administration, the Europe influenza vaccines market is divided into injection and nasal spray. The injection segment held a larger market share in 2022.
Based on country, the market is segmented into the UK, Germany, France, Italy, Spain, and the rest of Europe. The UK dominated the market share in 2022.
AstraZeneca; Emergent BioSolutions Inc.; GlaxoSmithKline plc.; Hualan Biological Engineering Inc.; Mitsubishi Chemical Group Corporation; Moderna, Inc.; MYLAN N.V.; Sanofi; SEQIRUS; and Serum Institute of India Pvt. Ltd are the leading companies operating in the influenza vaccines market in Europe.
Reasons to buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe Influenza Vaccines Market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Europe Influenza Vaccines Market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Influenza Vaccines Market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution
Table of Contents
139 Pages
- 1. Introduction
- 1.1 Study Scope
- 1.2 The Insight Partners Research Report Guidance
- 1.3 Market Segmentation
- 1.3.1 Europe Influenza Vaccines Market – By Vaccine Type
- 1.3.2 Europe Influenza Vaccines Market – By Virus Type
- 1.3.3 Europe Influenza Vaccines Market – By Technology
- 1.3.4 Europe Influenza Vaccines Market – By Route Of Administration
- 1.3.5 Europe Influenza Vaccines Market – By Country
- 2. Europe Influenza Vaccines Market – Key Takeaways
- 3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
- 4. Europe Influenza Vaccines Market – Market Landscape
- 4.1 Overview
- 4.2 PEST Analysis
- 4.2.1 Europe PEST Analysis
- 4.3 Experts Opinion
- 5. Europe Influenza Vaccines Market – Key Market Dynamics
- 5.1 Market Drivers
- 5.1.1 Rise in Government Support to Promote Influenza Vaccination
- 5.1.2 Increasing Investment by Top Market Players and Governments
- 5.2 Market Restraints
- 5.2.1 High Cost of Vaccine Development
- 5.3 Market Opportunities
- 5.3.1 Emerging Economies
- 5.4 Future Trends
- 5.4.1 Strong Pipeline Candidates for Influenza Vaccines
- 5.5 Impact Analysis
- 6. Influenza Vaccine Market – Europe Analysis
- 6.1 Europe Influenza Vaccines Market Revenue Forecasts And Analysis
- 7. Europe Influenza Vaccines Market– By Vaccine Type
- 7.1 Overview
- 7.2 Europe Influenza Vaccines Market, By Vaccine Type 2022 & 2028 (%)
- 7.3 Quadrivalent Vaccines
- 7.3.1 Overview
- 7.3.2 Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
- 7.4 Trivalent Vaccines
- 7.4.1 Overview
- 7.4.2 Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
- 8. Europe Influenza Vaccines Market– By Virus Type
- 8.1 Overview
- 8.2 Europe Influenza Vaccines Market, By Virus Type 2022 & 2028 (%)
- 8.3 Influenza Virus Type A
- 8.3.1 Overview
- 8.3.2 Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
- 8.4 Influenza Virus Type B
- 8.4.1 Overview
- 8.4.2 Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
- 9. Europe Influenza Vaccines Market – By Technology
- 9.1 Overview
- 9.2 Europe Influenza Vaccines Market, By Technology 2022 & 2028 (%)
- 9.3 Egg-Based
- 9.3.1 Overview
- 9.3.2 Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
- 9.4 Cell-Based
- 9.4.1 Overview
- 9.4.2 Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
- 10. Europe Influenza Vaccines Market– By Route of Administration
- 10.1 Overview
- 10.2 Europe Influenza Vaccines Market, By Route of Administration 2022 & 2028 (%)
- 10.3 Injection
- 10.3.1 Overview
- 10.3.2 Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
- 10.4 Nasal Spray
- 10.4.1 Overview
- 10.4.2 Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
- 11. Europe Influenza Vaccines Market – Country Analysis
- 11.1 Europe: Influenza Vaccines Market
- 11.1.1 Overview
- 11.1.2 Europe: Influenza Vaccines Market, by Country, 2022 & 2028 (%)
- 11.1.2.1 Germany: Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
- 11.1.2.1.1 Overview
- 11.1.2.1.2 Germany: Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
- 11.1.2.1.3 Germany: Influenza Vaccines Market, by Vaccine Type, 2019–2028 (US$ Million)
- 11.1.2.1.4 Germany: Influenza Vaccines Market, by Virus Type, 2019–2028 (US$ Million)
- 11.1.2.1.5 Germany: Influenza Vaccines Market, by Technology, 2019–2028 (US$ Million)
- 11.1.2.1.6 Germany: Influenza Vaccines Market, by Route of Administration, 2019–2028 (US$ Million)
- 11.1.2.2 UK: Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
- 11.1.2.2.1 Overview
- 11.1.2.2.2 UK: Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
- 11.1.2.2.3 UK: Influenza Vaccines Market, by Vaccine Type, 2019–2028 (US$ Million)
- 11.1.2.2.4 UK: Influenza Vaccines Market, by Virus Type, 2019–2028 (US$ Million)
- 11.1.2.2.5 UK: Influenza Vaccines Market, by Technology, 2019–2028 (US$ Million)
- 11.1.2.2.6 UK: Influenza Vaccines Market, by Route of Administration, 2019–2028 (US$ Million)
- 11.1.2.3 France: Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
- 11.1.2.3.1 Overview
- 11.1.2.3.2 France: Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
- 11.1.2.3.3 France: Influenza Vaccines Market, by Vaccine Type, 2019–2028 (US$ Million)
- 11.1.2.3.4 France: Influenza Vaccines Market, by Virus Type, 2019–2028 (US$ Million)
- 11.1.2.3.5 France: Influenza Vaccines Market, by Technology, 2019–2028 (US$ Million)
- 11.1.2.3.6 France: Influenza Vaccines Market, by Route of Administration, 2019–2028 (US$ Million)
- 11.1.2.4 Italy: Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
- 11.1.2.4.1 Overview
- 11.1.2.4.2 Italy: Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
- 11.1.2.4.3 Italy: Influenza Vaccines Market, by Vaccine Type, 2019–2028 (US$ Million)
- 11.1.2.4.4 Italy: Influenza Vaccines Market, by Virus Type, 2019–2028 (US$ Million)
- 11.1.2.4.5 Italy: Influenza Vaccines Market, by Technology, 2019–2028 (US$ Million)
- 11.1.2.4.6 Italy: Influenza Vaccines Market, by Route of Administration, 2019–2028 (US$ Million)
- 11.1.2.5 Spain: Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
- 11.1.2.5.1 Overview
- 11.1.2.5.2 Spain: Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
- 11.1.2.5.3 Spain: Influenza Vaccines Market, by Vaccine Type, 2019–2028 (US$ Million)
- 11.1.2.5.4 Spain: Influenza Vaccines Market, by Virus Type, 2019–2028 (US$ Million)
- 11.1.2.5.5 Spain: Influenza Vaccines Market, by Technology, 2019–2028 (US$ Million)
- 11.1.2.5.6 Spain: Influenza Vaccines Market, by Route of Administration, 2019–2028 (US$ Million)
- 11.1.2.6 Rest of Europe: Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
- 11.1.2.6.1 Overview
- 11.1.2.6.2 Rest of Europe: Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
- 11.1.2.6.3 Rest of Europe: Influenza Vaccines Market, by Vaccine Type, 2019–2028 (US$ Million)
- 11.1.2.6.4 Rest of Europe: Influenza Vaccines Market, by Virus Type, 2019–2028 (US$ Million)
- 11.1.2.6.5 Rest of Europe: Influenza Vaccines Market, by Technology, 2019–2028 (US$ Million)
- 11.1.2.6.6 Rest of Europe: Influenza Vaccines Market, by Route of Administration, 2019–2028 (US$ Million)
- 12. Europe Influenza Vaccine Market –Industry Landscape
- 12.1 Overview
- 12.2 Inorganic Growth Strategies
- 12.2.1 Overview
- 12.3 Organic Growth Strategies
- 12.3.1 Overview
- 13. Company Profiles
- 13.1 Moderna, Inc.
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
- 13.2 SEQIRUS
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
- 13.3 Sanofi
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
- 13.4 GlaxoSmithKline plc.
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
- 13.5 Hualan Biological Engineering Inc.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
- 13.6 Emergent BioSolutions Inc.
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
- 13.7 Mitsubishi Chemical Group Corporation
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
- 13.8 Serum Institute of India Pvt. Ltd
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
- 13.9 MYLAN N.V.
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
- 13.10 AstraZeneca
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
- 14. Appendix
- 14.1 About The Insight Partners
- 14.2 Glossary of Terms
- LIST OF TABLES
- Table 1. Europe Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
- Table 2. Germany Influenza Vaccines Market, by Vaccine Type – Revenue and Forecast to 2028 (US$ Million)
- Table 3. Germany: Influenza Vaccines Market, by Virus Type – Revenue and Forecast to 2028 (US$ Million)
- Table 4. Germany Influenza Vaccines Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
- Table 5. Germany Influenza Vaccines Market, by Route of Administration– Revenue and Forecast to 2028 (US$ Million)
- Table 6. UK Influenza Vaccines Market, by Vaccine Type – Revenue and Forecast to 2028 (US$ Million)
- Table 7. UK: Influenza Vaccines Market, by Virus Type – Revenue and Forecast to 2028 (US$ Million)
- Table 8. UK Influenza Vaccines Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
- Table 9. UK Influenza Vaccines Market, by Route of Administration– Revenue and Forecast to 2028 (US$ Million)
- Table 10. France Influenza Vaccines Market, by Vaccine Type – Revenue and Forecast to 2028 (US$ Million)
- Table 11. France: Influenza Vaccines Market, by Virus Type – Revenue and Forecast to 2028 (US$ Million)
- Table 12. France Influenza Vaccines Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
- Table 13. France Influenza Vaccines Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
- Table 14. Italy Influenza Vaccines Market, by Vaccine Type – Revenue and Forecast to 2028 (US$ Million)
- Table 15. Italy: Influenza Vaccines Market, by Virus Type – Revenue and Forecast to 2028 (US$ Million)
- Table 16. Italy Influenza Vaccines Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
- Table 17. Italy Influenza Vaccines Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
- Table 18. Spain Influenza Vaccines Market, by Vaccine Type – Revenue and Forecast to 2028 (US$ Million)
- Table 19. Spain: Influenza Vaccines Market, by Virus Type – Revenue and Forecast to 2028 (US$ Million)
- Table 20. Spain Influenza Vaccines Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
- Table 21. Spain Influenza Vaccines Market, by Route of Administration– Revenue and Forecast to 2028 (US$ Million)
- Table 22. Rest of Europe Influenza Vaccines Market, by Vaccine Type – Revenue and Forecast to 2028 (US$ Million)
- Table 23. Rest of Europe: Influenza Vaccines Market, by Virus Type – Revenue and Forecast to 2028 (US$ Million)
- Table 24. Rest of Europe Influenza Vaccines Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
- Table 25. Rest of Europe Influenza Vaccines Market, by Route of Administration– Revenue and Forecast to 2028 (US$ Million)
- Table 26. Recent Inorganic Growth Strategies in the Europe Influenza Vaccine Market
- Table 27. Recent Organic Growth Strategies in the Europe Influenza Vaccine Market
- Table 28. Glossary of Terms, Europe Influenza Vaccines Market
- LIST OF FIGURES
- Figure 1. Europe Influenza Vaccines Market Segmentation
- Figure 2. Europe Influenza Vaccines Market Segmentation, by Country
- Figure 3. Europe Influenza Vaccines Market Overview
- Figure 4. Quadrivalent Vaccines Segment Held Largest Share of Product Segment in Europe Influenza Vaccines Market
- Figure 5. UK Is Expected to Show Remarkable Growth During the Forecast Period
- Figure 7. Europe: PEST Analysis
- Figure 8. Experts Opinion
- Figure 9. Impact Analysis
- Figure 10. Europe Influenza Vaccines Market – Revenue Forecasts and Analysis – 2020- 2028
- Figure 11. Europe Influenza Vaccines Market, by Vaccine Type 2022 & 2028 (%)
- Figure 12. Europe Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
- Figure 13. Europe Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
- Figure 14. Europe Influenza Vaccines Market, by Virus Type 2022 & 2028 (%)
- Figure 15. Europe Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
- Figure 16. Europe Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
- Figure 17. Europe Influenza Vaccines Market, by Technology 2022 & 2028 (%)
- Figure 18. Europe Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
- Figure 19. Europe Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
- Figure 20. Europe Influenza Vaccines Market, by Route of Administration 2022 & 2028 (%)
- Figure 21. Europe Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
- Figure 22. Europe Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
- Figure 23. Europe: Influenza Vaccines Market, by Key Country – Revenue (2022) (US$ Million)
- Figure 24. Europe: Influenza Vaccines Market, by Country, 2022 & 2028 (%)
- Figure 25. Germany: Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
- Figure 26. UK: Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
- Figure 27. France: Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
- Figure 28. Italy: Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
- Figure 29. Spain: Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
- Figure 30. Rest of Europe: Influenza Vaccines Market – Revenue and Forecast to 2028 (US$ Million)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
